Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels
Pediatric and adolescent Crohn’s disease patients who switch to infliximab after losing responsiveness to adalimumab display lower drug...
Search results for "Crohn’s disease"
Oxalic Acid in Spinach and Almonds May Exacerbate Inflammatory Bowel Disease, Study Finds
Naturally occurring compounds in dietary staples such as spinach, beets, almonds, and cocoa—foods widely celebrated for their health benefits—may...
Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment
Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural...
When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients
Crohn’s disease remains one of the most challenging inflammatory bowel diseases to manage.
When Recurrent Diarrhea Is More Than a Passing Bug: The Rising Threat of IBD in Young Adults
When recurring abdominal pain and diarrhea strike, most people first assume they are dealing with a standard bout of...
The Gut-Brain Crisis: How Just Two Days of Sleep Deprivation Ravages the Digestive System
In a society where all-nighters—whether fueled by work pressure or entertainment—are often treated as a badge of...
Drooping Eyelids and Muscle Weakness? Pre-Existing Autoimmune Disease May Signal Myasthenia Gravis
Drooping eyelids, double vision, and unexplained muscle weakness in the arms and legs are classic warning signs of...
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal
Hanmi Pharmaceutical has licensed its novel drug candidate sonefpeglutide to global pharmaceutical giant Eli Lilly and...